When was Cellio Therapeutics founded?

Cellio Therapeutics was founded in 2023.

Where is Cellio Therapeutics located?

Cellio Therapeutics is headquartered in Los Angeles, United States.

Who is the current CEO of Cellio Therapeutics?

Steven Schwartz of Cellio Therapeutics.

Is Cellio Therapeutics a funded company?

Cellio Therapeutics is a funded company, having raised a total of $***** in its 1st and only funding round, a Grant (prize money) round.

When was the latest funding round of Cellio Therapeutics?

Cellio Therapeutics' latest funding was a $***** Grant (prize money) round, with participation from 1 investor.

Where does Cellio Therapeutics rank among its competitors?

Cellio Therapeutics ranks 3418th amongst 2781 active competitors, of which 924 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Cellio Therapeutics?

Cellio Therapeutics' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Cellio Therapeutics - 2026 Company Profile, Team, Funding & Competitors

Cellio Therapeutics is a funded company based in Los Angeles (United States), founded in 2023. It operates as a Developer of biomimetic nanoparticles for targeted cancer drug delivery. Cellio Therapeutics has raised an undisclosed amount in funding. The company has 2781 active competitors, including 924 funded and 647 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences.

Company Details

Developer of biomimetic nanoparticles for targeted cancer drug delivery. It combines chemotherapy or immunomodulatory agents, biodegradable biocompatible polymers, and natural cellular membranes to create targeted drug-delivery systems designed to improve treatment of solid tumors and accelerate the development of novel cancer therapies.

Key Metrics

Founded Year

2023

Location

Los Angeles, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), $*****

Investors

CIRM

Ranked

3418^th among 3418 competitors

Similar Companies

Liquidia & 374 more

View Cellio Therapeutics' full profile

Cellio Therapeutics has raised funding over 1 round. Its latest funding round was a Grant (prize money) round. 1 investor participated in its latest round. Cellio Therapeutics has 1 institutional investor.

View details of Cellio Therapeutics's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Cellio Therapeutics include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Cellio Therapeutics, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, F-Prime Capital & 18 others	73/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
3418th	Cellio Therapeutics 2023, Los Angeles (United States), Funding Raised	Developer of biomimetic nanoparticles for targeted cancer drug delivery	-	CIRM	-